Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
Slika profila

Hrvoje Holik

42268

Hrvoje

Holik

nije evidentirano
Naziv Akcije
Krečak, Ivan ; Zekanović, Ivan ; Morić Perić, Martina ; Holik, Hrvoje ; Coha, Božena ; Periša, Vlatka ; Lucijanić, Marko High plateletcrit may be associated with thrombotic risk in polycythemia vera // International journal of laboratory hematology, (2023), doi: 10.1111/ijlh.14073
Holik, Hrvoje ; Lucijanic, Marko ; Krecak, Ivan Specific symptom burden in patients with chronic myeloproliferative neoplasms and chronic kidney disease // Annals of hematology, (2023), doi: 10.1007/s00277-023-05296-1
Krečak, Ivan ; Grohovac, Dragana ; Vučenović Bašić, Nikolina ; Čeko, Monika ; Nižetić, Karla ; Sabljić, Anica ; Holik, Hrvoje ; Galušić, Davor ; Zekanović, Ivan ; Morić Perić, Martina et al. Clinical presentation, treatment patterns, and outcomes of pulmonary embolism in patients with chronic myeloproliferative neoplasms // Thrombosis research, (2023), doi: 10.1016/j.thromres.2023.03.004
Lucijanić, Marko ; Krečak, Ivan ; Sorić, Ena ; Galušić, Davor ; Holik, Hrvoje ; Periša, Vlatka ; Morić Perić, Martina ; Zekanović, Ivan ; Kušec, Rajko Palpable spleen size is differently prognostic in primary and secondary myelofibrosis // Leukemia & lymphoma, 64 (2023), 4; 893-896. doi: 10.1080/10428194.2023.2179360
Lucijanic, Marko ; Krecak, Ivan ; Soric, Ena ; Sabljic, Anica ; Galusic, Davor ; Holik, Hrvoje ; Perisa, Vlatka ; Peric, Martina Moric ; Zekanovic, Ivan ; Kusec, Rajko Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis // Biochemia medica, 33 (2023), 2; 020901, 8. doi: 10.11613/bm.2023.020901
(HRZZ-UIP-2020-02-8189) Šimičević, Livija ; Slišković, Ana Marija ; Vrkić Kirhmajer, Majda ; Ganoci Lana ; Holik, Hrvoje ; Palić, Jozefina ; Samardžić, Jure ; Božina, Tamara Risk Factors for Rivaroxaban-Related Bleeding Events-Possible Role of Pharmacogenetics: Case Series // Pharmacy (Basel), 11 (2023), 1; 29, 19. doi: 10.3390/pharmacy11010029
(KroHem) Mitrović, Zdravko ; Dujmović, Dino ; Jakšić, Ozren ; Bašić-Kinda, Sandra ; Gaćina, Petar ; Periša, Vlatka ; Prka, Željko ; Dreta, Barbara ; Galušić Davor ; Holik, Hrvoje et al. Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem) // European journal of haematology, 111 (2023), 13957, 7. doi: 10.1111/ejh.13957
Slišković, Ana Marija ; Šimičević, Livija ; Vrkić Kirhmajer, Majda ; Ganoci, Lana ; Holik, Hrvoje ; Samardžić, Jure ; Božina, Tamara Krvarenja povezana s primjenom rivaroksabana - moguća uloga farmakogenetike kao rizičnog čimbenika // 3. hrvatski kongres KLINIČKE FARMACIJE Klinička farmacija u sustavu zdravstva: MOGUĆNOSTI I IZAZOVI Zagreb, Hrvatska, 09.06.2022-11.06.2022
Krečak, Ivan ; Holik, Hrvoje ; Lucijanić, Marko The Prevalence of Simple Kidney Cysts in Polycythemia Vera and Its Clinical Associations // Indian Journal of Hematology and Blood Transfusion, 38 (2022), 2; 429-431. doi: 10.1007/s12288-021-01515-9
Šimičević, Livija ; Slišković, Ana Marija ; Vrkić Kirhmajer, Majda ; Ganoci, Lana ; Holik, Hrvoje ; Samardžić, Jure ; Božina, Tamara The role of pharmacogenetics as possible risk factor for rivaroxaban - associated bleeding // Pharmaca. 2022. str. 141-141
nije evidentirano
nije evidentirano